Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HNSN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with HNSN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies  
Compare:NAS:LAKE, AMEX:BVX, NAS:EKSO, NAS:HBIO, NAS:BIOL, NAS:LENS, AMEX:INFU, NAS:VLRX, OTCPK:TSNLF, AMEX:MLSS, NAS:CASM, AMEX:RVP, AMEX:ISR, OTCPK:UNISQ, OTCPK:TDMMF, AMEX:DXR, NAS:BLFS, NAS:ATEC, OTCBB:NEPH, NAS:BMRA » details
Headquarter Location:USA
Hansen Medical Inc develops, manufactures and markets medical robotics designed for accurate positioning, manipulation and stable control of catheters and catheter-based technologies.

Hansen Medical Inc, formerly known as AutoCath Inc, was incorporated in Delaware in 2002. The Company completed its initial public offering on February 28, 2014. The Company develops, manufactures and sells medical robotics designed for accurate positioning, manipulation and stable control of catheters and catheter-based technologies. Its products include Sensei Robotic Catheter System, Magellan Robotic System, Artisan catheter, Lynx catheter, Magellan Robotic Catheter, and CoHesion 3D Visualization Module. Sensei Robotic Catheter System, or Sensei system, is designed to allow physicians to navigate flexible catheters with solid stability and control in interventional procedures within the atrial heart chambers. This system enables physicians to direct the movements of a robotic catheter like the Company's Artisan Control Catheter and Artisan Extend Control Catheter, or Artisan catheters, and Lynx Robotic Ablation Catheter, or Lynx catheter, to an anatomical location. The Sensei system is comprised of two modules: a physician control console and a patient-side module that can be connected to procedure tables. The control console can be located inside the Electro-Physiology Laboratory, or EP lab, and close to the patient or outside the EP lab in a separate location shielded from radiation. The Company's Magellan Robotic System is a peripheral vascular interventional platform that, used in combination with the Magellan Robotic Catheters, has the potential to provide endovascular specialists with vessel navigation, catheter stability during the manual delivery and placement of therapeutic devices, reduced procedural radiation exposure and fatigue, and precise robotic control of distal catheter tips. Magellan Robotic System is comprised of two modules: a physician control console and a patient-side robotic arm that can be connected to procedure tables. The Artisan catheter is a disposable catheter and guide catheter assembly that consists of a telescoping set of control catheters that are integrated to provide the desired motion of the tip of a diagnostic or therapeutic catheter that is inserted through the center lumen of the Artisan catheter. This is designed to accurately control the movement of a third party catheter chosen by the physician. CoHesion 3D Visualization Module, or CoHesion Module, is a software interface between Sensei system and the St. Jude Medical EnSite System for EP procedures. It is designed to provide physicians with 3D visualization to augment their ability to move a catheter throughout the atria, as well as increase control over placement of the catheter in specific locations. The Company markets, sells and supports its products in the United States through a direct sales force of regional sales employees, supported by clinical account managers who provide training, clinical support and other services to customers. Outside the United States, in the European Union, it uses a combination of a direct sales for

Top Ranked Articles about Hansen Medical Inc

Hansen Medical(R) Announces Filing of 510K for Expanded Neurological Indication for Magellan(TM) Product Line

MOUNTAIN VIEW, CA--(Marketwired - Apr 26, 2016) - Hansen Medical®, Inc. (NASDAQ: HNSN), the global leader in intravascular robotics, today provides an update on the status of its key corporate initiative to expand the utility and regulatory labeling of the Magellan™ product line. Hansen Medical recently submitted a 510k to the FDA for a neurological indication for the Magellan Robotic System. If successful, the Magellan Robotic System would be fully indicated for applications in peripheral vascular and neurological procedures. "Our experience in performing robotically assisted carotid stent procedures has shown that there could be important advantages for neuro applications including many of the benefits we have seen in other applications, like embolization and other endovascular therapies," said Barry T. Katzen, MD of Miami Cardiac & Vascular Institute in Miami, FL. "We anticipate that an added neurological indication would allow us to bring the benefits of robotics to a new specialty of physicians who could, in turn, offer robotic solutions to a new patient population," said Cary Vance, Hansen Medical's President and Chief Executive Officer. "We are excited by the potential to expand the procedure base in which robotics can play a role." About the Magellan™ Robotic System

Hansen Medical's Magellan Robotic System is intended to be used to facilitate navigation in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Magellan Robotic System is designed to deliver predictability, control and catheter stability to endovascular procedures. Since its commercial introduction in the U.S. and Europe, the Magellan Robotic System has demonstrated its clinical versatility in many cases in a broad variety of peripheral vascular procedures globally. The Magellan Robotic System offers several important features including:

Provides predictability, control and catheter stability as a physician navigates a patient's peripheral vasculature and then provides a conduit for manual treatment of vascular disease with standard therapeutic devices.
Is designed to enable more predictable procedure times and increased case throughput potentially allowing hospitals to improve utilization within their vascular business line.
Employs an open architecture designed to allow for the subsequent use of many therapeutic devices on the market today.
Is designed to potentially reduce physician radiation exposure and fatigue by allowing the physician to navigate procedures while seated comfortably at a remote workstation away from the radiation field and without wearing heavy lead as required in conventional endovascular procedures.
The Magellan 9Fr and 10Fr Robotic Catheters allow for independent, robotic control of two telescoping catheters (an outer Guide and an inner Leader catheter), as well as robotic manipulation of standard guide wires.
The Magellan 6Fr Robotic Catheter allows for independent robotic control of two separate bend sites on a single catheter, as well as robotic manipulation of standard guide wires. This smaller catheter design may be preferred by certain physicians who prefer a smaller diameter vessel access site, or in procedures in smaller vessels.
The Magellan Robotic Catheter eKit provides robotic control of 3rd party microcatheters through a robotic catheter with dual-bend technology. This configuration may provide an additional level of robotic control during procedures in which therapy is delivered through a microcatheter.

About Hansen Medical, Inc.

Hansen Medical, Inc., based in Mountain View, California, is the global leader in Intravascular Robotics, developing products and technology designed to enable the accurate positioning, manipulation and control of catheters and catheter-based technologies. The Company's Magellan™ Robotic System, Magellan Robotic Catheters, and related accessories are intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Company's mission is to enable cardiac arrhythmia and endovascular procedures and to improve patient outcomes through the use of intravascular robotics. Additional information can be found at www.hansenmedical.com. "Hansen Medical," "Hansen Medical (with Heart Design)," and "Heart Design (Logo)" are registered trademarks, and "Magellan" and "Hansen Medical Magellan" are trademarks of Hansen Medical, Inc. in the U.S. and other countries. All other trademarks are the property of their respective owners. Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "plan," "expects," "potential," "believes," "goal," "estimate," "anticipates," and other similar words. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances and other factors that may cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Examples of such statements include statements regarding the potential benefits of our robotic systems for hospitals, patients and physicians. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: factors relating to engineering, regulatory, manufacturing, sales and customer service challenges in developing new products and entering new markets; potential safety and regulatory issues that could slow or suspend our sales; the effect of credit, financial and economic conditions on capital spending by our potential customers; the rate of adoption of our systems and the rate of use of our catheters; our ability to manage expenses and cash flow, and obtain adequate financing; and other risks more fully described in the "Risk Factors" in Hansen Medical's Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 and Hansen Medical's other filings with the Securities and Exchange Commission. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.







Read more...
Hansen Medical(R) to Highlight Benefits and Future of Magellan(TM) Robotic System Technology and Present Magellan Robotic System at Charing Cross International Symposium

MOUNTAIN VIEW, CA--(Marketwired - Apr 25, 2016) - Hansen Medical®, Inc. (NASDAQ: HNSN), the global leader in intravascular robotics, today announced it will exhibit its Magellan™ Robotic System at the Charing Cross International Symposium in London, United Kingdom from April 26th to April 29th. At the 38th annual symposium, the Magellan Robotic System and family of Magellan Robotic Catheters will be showcased and available for demonstrations at exhibit booth #215. Hansen Medical also anticipates that intravascular robotics will be discussed during the following sessions at Charing Cross:

April 26, 14:40, Robotic-assisted endovascular aneurysm repairs: improved efficiency compared to manual techniques for contralateral gate cannulation- Celia Riga, MD (London, UK)
April 27, 10:40, Case experience of iliac artery treatment with robotic hybrid approach- Fabien Thaveau, MD (Strasbourg, France)
April 27, 12:10, The Magellan Robotic Catheter eKit and potential for radiation dose reduction- Celia Riga, MD (London, UK)
April 28, 08:14, Improving procedural success in complex pathologies with robotics and advanced imaging - Barry Katzen, MD (Miami, US)
April 28, 08:30, Successful use of robotics in failed treatment of central venous stenosis - Alan Lumsden, MD (Houston, US)
April 28, 08:37, Inferior vena cava filter retrieval with robotics - Alan Lumsden, MD (Houston, US)
April 28, 09:37, Robotic benefits for endovascular procedures - Celia Riga, MD (London, UK)
April 28, 14:33, Methods to reduce radiation exposure during endovascular procedures - Barry Katzen, MD (Miami, US)
April 28, 15:45, The role of robotics in advanced endovascular procedures, Celia Riga, MD, (London, UK)

Additionally, Hansen Medical will host two physician presentations at its booth as a part of CX Imaging Day. These will focus on new clinical data and experiences with the current system and insights from Dr. Lumsden about his research with future robotic technology. The presentations include:

April 28, 12:30, Clinical Experiences with Intravascular Robotics, Barry Katzen, MD (Miami, US) (Hansen Booth 215)
April 28, 15:45, Flexible Robotics with Electromagnetic Tracking and the Impacts of Safety & Efficiency, Alan Lumsden, MD (Houston, US) (Hansen Booth 215)

"We are looking forward to having a strong presence at Charing Cross this year and are eager to connect with the vascular and endovascular community," said Cary Vance, Hansen Medical's President and Chief Executive Officer. "Our present Magellan users have gained great insights in clinical and research applications both with current and future technology, and we positively anticipate the new data and case reports that they will highlight during the symposium." The Magellan Robotic System is an advanced technology that drives Magellan Robotic Catheters and guide wires during minimally-invasive, endovascular procedures. Magellan is designed to offer procedural predictability, precision, and catheter stability as physicians navigate inside blood vessels and deliver therapy. Image-guided medical procedures using interventional fluoroscopy, while growing rapidly, are the leading source of occupational ionizing radiation exposure for medical personnel1. Magellan's remote workstation allows physicians to control robotic catheters and guide wires while seated away from the radiation field, which has been shown to reduce radiation exposure for the physician by as much as 95% in complex endovascular procedures2. About the Magellan™ Robotic System

Hansen Medical's Magellan Robotic System is intended to be used to facilitate navigation in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Magellan Robotic System is designed to deliver predictability, control and catheter stability to endovascular procedures. Since its commercial introduction in the U.S. and Europe, the Magellan Robotic System has demonstrated its clinical versatility in many cases in a broad variety of peripheral vascular procedures globally. The Magellan Robotic System offers several important features including:

Provides predictability, control and catheter stability as a physician navigates a patient's peripheral vasculature and then provides a conduit for manual treatment of vascular disease with standard therapeutic devices.
Is designed to enable more predictable procedure times and increased case throughput potentially allowing hospitals to improve utilization within their vascular business line.
Employs an open architecture designed to allow for the subsequent use of many therapeutic devices on the market today.
Is designed to potentially reduce physician radiation exposure and fatigue by allowing the physician to navigate procedures while seated comfortably at a remote workstation away from the radiation field and without wearing heavy lead as required in conventional endovascular procedures.
The Magellan Robotic Catheter 9Fr and 10Fr allow for independent, robotic control of two telescoping catheters (an outer Guide and an inner Leader catheter), as well as robotic manipulation of standard guide wires.
The Magellan Robotic Catheter 6Fr allows for independent robotic control of two separate bend sites on a single catheter, as well as robotic manipulation of standard guide wires. This smaller catheter design may be preferred by certain physicians who prefer a smaller diameter vessel access site, or in procedures in smaller vessels.
The Magellan Robotic Catheter eKit provides robotic control of 3rd party microcatheters through a robotic catheter with dual-bend technology. This configuration may provide an additional level of robotic control during procedures in which therapy is delivered through a microcatheter.

About Hansen Medical, Inc.

Hansen Medical, Inc., based in Mountain View, California, is the global leader in Intravascular Robotics, developing products and technology designed to enable the accurate positioning, manipulation and control of catheters and catheter-based technologies. The Company's Magellan™ Robotic System, Magellan Robotic Catheters, and related accessories are intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Company's mission is to enable cardiac arrhythmia and endovascular procedures and to improve patient outcomes through the use of intravascular robotics. Additional information can be found at www.hansenmedical.com. "Hansen Medical," "Hansen Medical (with Heart Design)," and "Heart Design (Logo)" are registered trademarks, and "Magellan" and "Hansen Medical Magellan" are trademarks of Hansen Medical, Inc. in the U.S. and other countries. All other trademarks are the property of their respective owners. Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "plan," "expects," "potential," "believes," "goal," "estimate," "anticipates," and other similar words. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances and other factors that may cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Examples of such statements include statements regarding the potential benefits of our robotic systems for hospitals, patients and physicians. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: factors relating to engineering, regulatory, manufacturing, sales and customer service challenges in developing new products and entering new markets; potential safety and regulatory issues that could slow or suspend our sales; the effect of credit, financial and economic conditions on capital spending by our potential customers; the rate of adoption of our systems and the rate of use of our catheters; our ability to manage expenses and cash flow, and obtain adequate financing; and other risks more fully described in the "Risk Factors" in Hansen Medical's Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 and Hansen Medical's other filings with the Securities and Exchange Commission. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. 1 U.S. Environmental Protection Agency of Radiation Protection Programs Home Page; Health Effects, http://www.epa.gov/rpdweb00/understand/health_effects.html (Accessed on November 10, 2014) 2 Robotic Catheter Assistance: The Relationship on Radiation Exposure, presentation by Barry Katzen, MD during Charing Cross International Symposium, London, April 29, 2015.







Read more...

Ratios

vs
industry
vs
history

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $13.32
EPS (TTM) $ -4.55
Short Percentage of Float1.96%
52-Week Range $1.28 - 9.10
Shares Outstanding (Mil)18.99
» More Articles for HNSN

Headlines

Articles On GuruFocus.com
Hansen Medical(R) Announces Filing of 510K for Expanded Neurological Indication for Magellan(TM) Pro Apr 26 2016 
Hansen Medical(R) to Highlight Benefits and Future of Magellan(TM) Robotic System Technology and Pre Apr 25 2016 
Auris Surgical Robotics Agrees to Acquire Hansen Medical Apr 20 2016 
Hansen Medical(R), Inc. Receives NASDAQ Letter Regarding Late Form 10-K Filing Apr 06 2016 
Hansen Medical(R) to Demonstrate New Magellan(TM) Robotic Catheter eKit and Present Magellan Robotic Mar 17 2016 
Hansen Medical(R) Announces First Clinical Procedure in the US With New Magellan(TM) Robotic Cathete Feb 17 2016 
Hansen Medical(R) Announces FDA Clearance of the Magellan(TM) Robotic Catheter eKit Feb 02 2016 
Hansen Medical(R) Announces Latest Publication in the Journal of Interventional Cardiac Electrophysi Feb 01 2016 
Hansen Medical Provides Corporate Update of Key Near-Term Clinical, Regulatory and Commercial Events Jan 14 2016 
Hansen Medical Announces Exploration of Strategic Alternatives Jan 14 2016 

More From Other Websites
HANSEN MEDICAL SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Hansen... Apr 27 2016
INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Hansen Medical,... Apr 26 2016
Hansen Medical(R) Announces Filing of 510K for Expanded Neurological Indication for Magellan(TM)... Apr 26 2016
Hansen Medical(R) to Highlight Benefits and Future of Magellan(TM) Robotic System Technology and... Apr 25 2016
Ryan & Maniskas, LLP Announces Investigation of Hansen Medical, Inc. Apr 22 2016
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Hansen... Apr 20 2016
Hansen Medical Agrees To Sell Itself To Auris Surgical Robotics For A 40% Premium Apr 20 2016
Don’t Miss Out On These Five Surging Stocks Today Apr 20 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation as to Whether the Sale of Hansen... Apr 20 2016
Auris Surgical Robotics Agrees to Acquire Hansen Medical Apr 20 2016
Hansen Medical(R), Inc. Receives NASDAQ Letter Regarding Late Form 10-K Filing Apr 06 2016
Hansen Medical(R) to Demonstrate New Magellan(TM) Robotic Catheter eKit and Present Magellan Robotic... Mar 17 2016
Hansen Medical(R) Announces First Clinical Procedure in the US With New Magellan(TM) Robotic... Feb 17 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)